{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:51:10Z","timestamp":1782438670383,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangxi Provincial Natural Science Foundation of China grants"},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M710853"],"award-info":[{"award-number":["2022M710853"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/aims<\/jats:title>\n                <jats:p>This study explores the relationship between the E3 ubiquitin ligase Ring finger protein 126 (RNF126) and early breast cancer metastasis and tests the hypothesis that RNF126 determines the efficacy of inhibitors targeting Ataxia telangiectasia mutated and Rad3-related kinase (ATR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Various metastasis-related genes were identified by univariable Cox proportional hazards regression analysis based on the GSE11121 dataset. The RNF126-related network modules were identified by WGCNA, whereas cell viability, invasion, and migration assays were performed to evaluate the biological characteristics of breast cancer cells with or without RNF126 knockdown. MTT, immunoblotting, immunofluorescence, and DNA fiber assays were conducted to determine the efficiency of ATR inhibitor in cells with or without RNF126 knockdown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>RNF126 was associated with early breast cancer metastasis. RNF126 promoted breast cancer cell proliferation, growth, migration, and invasion. ATR inhibitors were more effective at killing breast cancer cells with intact RNF126 due to replication stress compared with the corresponding cells with RNF126 knockdown. Cyclin-dependent kinase 2 (CDK2) was involved in regulating replication stress in breast cancer cells with intact RNF126.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A high level of expression of RNF126 in early breast cancer patients without lymph node metastases may indicate a high-risk type of metastatic disease, possibly due to RNF126, which may increase breast cancer cell proliferation and invasion. RNF126-expressing breast cancer cells exhibit CDK2-mediated replication stress that makes them potential targets for ATR inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-022-01586-0","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T09:07:46Z","timestamp":1671527266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors"],"prefix":"10.1186","volume":"24","author":[{"given":"You","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longgui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danke","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"1586_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"key":"1586_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316\u201323. https:\/\/doi.org\/10.1038\/nature03097.","journal-title":"Nature"},{"key":"1586_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med"},{"key":"1586_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the st. Gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol"},{"key":"1586_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287\u201394. https:\/\/doi.org\/10.1038\/nature10760.","journal-title":"Nature"},{"key":"1586_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124\u201338. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.12.001.","journal-title":"Pharmacol Ther"},{"key":"1586_CR7","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.1074\/jbc.M110.204065","volume":"286","author":"SV Kozlov","year":"2011","unstructured":"Kozlov SV, Graham ME, Jakob B, Tobias F, Kijas AW, Tanuji M, et al. Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem. 2011;286:9107\u201319. https:\/\/doi.org\/10.1074\/jbc.M110.204065.","journal-title":"J Biol Chem"},{"key":"1586_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.21873\/anticanres.14078","volume":"40","author":"K Migita","year":"2020","unstructured":"Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, et al. Rnf126 as a marker of prognosis and proliferation of gastric cancer. Anticancer Res. 2020;40:1367\u201374. https:\/\/doi.org\/10.21873\/anticanres.14078.","journal-title":"Anticancer Res"},{"key":"1586_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.gpb.2018.07.004","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang Z, Shi R, Zhu X, Zhou J, Peng B, et al. Rnf126 quenches rnf168 function in the DNA damage response. Genomics Proteomics Bioinform. 2018;16:428\u201338. https:\/\/doi.org\/10.1016\/j.gpb.2018.07.004.","journal-title":"Genomics Proteomics Bioinform"},{"key":"1586_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.09.025","author":"P Fa","year":"2021","unstructured":"Fa P, Qiu Z, Wang QE, Yan C, Zhang J. A novel role for rnf126 in the promotion of g2 arrest via interaction with 14-3-3sigma. Int J Radiat Oncol Biol Phys. 2021. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.025.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1586_CR11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/cam4.771","volume":"5","author":"L Wang","year":"2016","unstructured":"Wang L, Wang X, Zhao Y, Niu W, Ma G, Yin W, et al. E3 ubiquitin ligase rnf126 regulates the progression of tongue cancer. Cancer Med. 2016;5:2043\u20137. https:\/\/doi.org\/10.1002\/cam4.771.","journal-title":"Cancer Med"},{"key":"1586_CR12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/onc.2015.198","volume":"35","author":"Y Wang","year":"2016","unstructured":"Wang Y, Deng O, Feng Z, Du Z, Xiong X, Lai J, et al. Rnf126 promotes homologous recombination via regulation of e2f1-mediated brca1 expression. Oncogene. 2016;35:1363\u201372. https:\/\/doi.org\/10.1038\/onc.2015.198.","journal-title":"Oncogene"},{"key":"1586_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00347-16","author":"N Ishida","year":"2017","unstructured":"Ishida N, Nakagawa T, Iemura SI, Yasui A, Shima H, Katoh Y, et al. Ubiquitylation of ku80 by rnf126 promotes completion of nonhomologous end joining-mediated DNA repair. Mol Cell Biol. 2017. https:\/\/doi.org\/10.1128\/MCB.00347-16.","journal-title":"Mol Cell Biol"},{"key":"1586_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716","author":"A Marechal","year":"2013","unstructured":"Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013. https:\/\/doi.org\/10.1101\/cshperspect.a012716.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1586_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","volume":"78","author":"JM Cleary","year":"2020","unstructured":"Cleary JM, Aguirre AJ, Shapiro GI, D\u2019Andrea AD. Biomarker-guided development of DNA repair inhibitors. Mol Cell. 2020;78:1070\u201385. https:\/\/doi.org\/10.1016\/j.molcel.2020.04.035.","journal-title":"Mol Cell"},{"key":"1586_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013;155:1088\u2013103. https:\/\/doi.org\/10.1016\/j.cell.2013.10.043.","journal-title":"Cell"},{"key":"1586_CR17","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","volume":"73","author":"CJ Huntoon","year":"2013","unstructured":"Huntoon CJ, Flatten KS, Wahner HA, Huehls AM, Sutor SL, Kaufmann SH, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013;73:3683\u201391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0110.","journal-title":"Cancer Res"},{"key":"1586_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.4161\/cbt.21093","volume":"13","author":"R Prevo","year":"2012","unstructured":"Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, et al. The novel ATR inhibitor ve-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13:1072\u201381. https:\/\/doi.org\/10.4161\/cbt.21093.","journal-title":"Cancer Biol Ther"},{"key":"1586_CR19","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","volume":"74","author":"R Josse","year":"2014","unstructured":"Josse R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, et al. ATR inhibitors ve-821 and vx-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014;74:6968\u201379. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3369.","journal-title":"Cancer Res"},{"key":"1586_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.1257216","volume":"347","author":"RL Flynn","year":"2015","unstructured":"Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015;347:273\u20137. https:\/\/doi.org\/10.1126\/science.1257216.","journal-title":"Science"},{"key":"1586_CR21","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","volume":"74","author":"KN Mohni","year":"2014","unstructured":"Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ercc1 deficiency. Cancer Res. 2014;74:2835\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3229.","journal-title":"Cancer Res"},{"key":"1586_CR22","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","volume":"68","author":"M Schmidt","year":"2008","unstructured":"Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68:5405\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5206.","journal-title":"Cancer Res"},{"key":"1586_CR23","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1128\/MCB.02278-06","volume":"27","author":"JA Seiler","year":"2007","unstructured":"Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-s-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol. 2007;27:5806\u201318. https:\/\/doi.org\/10.1128\/MCB.02278-06.","journal-title":"Mol Cell Biol"},{"key":"1586_CR24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1078-0432.CCR-17-2242","volume":"24","author":"X Yang","year":"2018","unstructured":"Yang X, Pan Y, Qiu Z, Du Z, Zhang Y, Fa P, et al. Rnf126 as a biomarker of a poor prognosis in invasive breast cancer and chek1 inhibitor efficacy in breast cancer cells. Clin Cancer Res. 2018;24:1629\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2242.","journal-title":"Clin Cancer Res"},{"key":"1586_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622\u201336. https:\/\/doi.org\/10.1038\/nrm.2017.67.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1586_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.celrep.2015.12.032","volume":"14","author":"K Sanjiv","year":"2016","unstructured":"Sanjiv K, Hagenkort A, Calderon-Montano JM, Koolmeister T, Reaper PM, Mortusewicz O, et al. Cancer-specific synthetic lethality between ATR and Chk1 kinase activities. Cell Rep. 2016;14:298\u2013309. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.032.","journal-title":"Cell Rep"},{"key":"1586_CR27","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1158\/1078-0432.CCR-17-2701","volume":"24","author":"ZY Oo","year":"2018","unstructured":"Oo ZY, Stevenson AJ, Proctor M, Daignault SM, Walpole S, Lanagan C, et al. Endogenous replication stress marks melanomas sensitive to chek1 inhibitors in vivo. Clin Cancer Res. 2018;24:2901\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2701.","journal-title":"Clin Cancer Res"},{"key":"1586_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nrc2523","volume":"8","author":"WM Bonner","year":"2008","unstructured":"Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. Gammah2ax and cancer. Nat Rev Cancer. 2008;8:957\u201367. https:\/\/doi.org\/10.1038\/nrc2523.","journal-title":"Nat Rev Cancer"},{"key":"1586_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/Chk1 inhibitors and cancer therapy. Radiother Oncol. 2018;126:450\u201364. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.043.","journal-title":"Radiother Oncol"},{"key":"1586_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ijc.32966","volume":"147","author":"A Patel","year":"2020","unstructured":"Patel A, Seraia E, Ebner D, Ryan AJ. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. Int J Cancer. 2020;147:1474\u201384. https:\/\/doi.org\/10.1002\/ijc.32966.","journal-title":"Int J Cancer"},{"key":"1586_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/15384101.2016.1152424","volume":"15","author":"C Kohler","year":"2016","unstructured":"Kohler C, Koalick D, Fabricius A, Parplys AC, Borgmann K, Pospiech H, et al. Cdc45 is limiting for replication initiation in humans. Cell Cycle. 2016;15:974\u201385. https:\/\/doi.org\/10.1080\/15384101.2016.1152424.","journal-title":"Cell Cycle"},{"key":"1586_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1083\/jcb.200104099","volume":"154","author":"C Feijoo","year":"2001","unstructured":"Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-s phase checkpoint monitoring replication origin firing. J Cell Biol. 2001;154:913\u201323. https:\/\/doi.org\/10.1083\/jcb.200104099.","journal-title":"J Cell Biol"},{"key":"1586_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/07853890.2014.892296","volume":"46","author":"M Sotak","year":"2014","unstructured":"Sotak M, Sumova A, Pacha J. Cross-talk between the circadian clock and the cell cycle in cancer. Ann Med. 2014;46:221\u201332. https:\/\/doi.org\/10.3109\/07853890.2014.892296.","journal-title":"Ann Med"},{"key":"1586_CR34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1101\/gad.1632808","volume":"22","author":"XH Yang","year":"2008","unstructured":"Yang XH, Shiotani B, Classon M, Zou L. Chk1 and Claspin potentiate PCNA ubiquitination. Genes Dev. 2008;22:1147\u201352. https:\/\/doi.org\/10.1101\/gad.1632808.","journal-title":"Genes Dev"},{"key":"1586_CR35","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","volume":"27","author":"FB Couch","year":"2013","unstructured":"Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Betous R, et al. ATR phosphorylates smarcal1 to prevent replication fork collapse. Genes Dev. 2013;27:1610\u201323. https:\/\/doi.org\/10.1101\/gad.214080.113.","journal-title":"Genes Dev"},{"key":"1586_CR36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson R, Boisvert JL, Benes CH, Zou L. Distinct but concerted roles of ATR, DNA-pk, and Chk1 in countering replication stress during s phase. Mol Cell. 2015;59:1011\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2015.07.029.","journal-title":"Mol Cell"},{"key":"1586_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1541-7786.MCR-20-0414","volume":"19","author":"K Ramkumar","year":"2021","unstructured":"Ramkumar K, Stewart CA, Cargill KR, Della CC, Wang Q, Shen L, et al. AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors. Mol Cancer Res. 2021;19:485\u201397. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0414.","journal-title":"Mol Cancer Res"},{"key":"1586_CR38","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/onc.2012.387","volume":"32","author":"RM Jones","year":"2013","unstructured":"Jones RM, Mortusewicz O, Afzal I, Lorvellec M, Garcia P, Helleday T, et al. Increased replication initiation and conflicts with transcription underlie cyclin e-induced replication stress. Oncogene. 2013;32:3744\u201353. https:\/\/doi.org\/10.1038\/onc.2012.387.","journal-title":"Oncogene"},{"key":"1586_CR39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","volume":"145","author":"AC Bester","year":"2011","unstructured":"Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435\u201346. https:\/\/doi.org\/10.1016\/j.cell.2011.03.044.","journal-title":"Cell"},{"key":"1586_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.molcel.2018.12.021","volume":"73","author":"L Deng","year":"2019","unstructured":"Deng L, Wu RA, Sonneville R, Kochenova OV, Labib K, Pellman D, et al. Mitotic CDK promotes replisome disassembly, fork breakage, and complex DNA rearrangements. Mol Cell. 2019;73:915\u201329. https:\/\/doi.org\/10.1016\/j.molcel.2018.12.021.","journal-title":"Mol Cell"},{"key":"1586_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/0008-5472.CAN-12-0562","volume":"73","author":"X Zhi","year":"2013","unstructured":"Zhi X, Zhao D, Wang Z, Zhou Z, Wang C, Chen W, et al. E3 ubiquitin ligase rnf126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res. 2013;73:385\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0562.","journal-title":"Cancer Res"},{"key":"1586_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.22074\/cellj.2022.8035","volume":"24","author":"B Ge","year":"2022","unstructured":"Ge B, Zhang X, Zhou W, Mo Y, Su ZH, Xu G, et al. Linc00265 promotes metastasis and progression of hepatocellular carcinoma by interacting with e2f1 at the promoter of CDK2. Cell J. 2022;24:294\u2013301. https:\/\/doi.org\/10.22074\/cellj.2022.8035.","journal-title":"Cell J"},{"key":"1586_CR43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in tp53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127:582\u201395. https:\/\/doi.org\/10.1182\/blood-2015-05-644872.","journal-title":"Blood"},{"key":"1586_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI58928","volume":"122","author":"DW Schoppy","year":"2012","unstructured":"Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M, et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest. 2012;122:241\u201352. https:\/\/doi.org\/10.1172\/JCI58928.","journal-title":"J Clin Invest"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-022-01586-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T03:04:07Z","timestamp":1671851047000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-022-01586-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1186\/s13058-022-01586-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"20 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experiments were carried out with the approval of the guidelines of Guangxi Medical University Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential competing interests were disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}